Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|RTOG-1216||RTOG||Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1308||RTOG||Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy For Inoperable Stage II-IIIB NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-BR-0118||RTOG||A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-P-0011||RTOG||Phase III Randomized Study of Adjuvant Therapy For High Risk PT2-3N0 Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-P-0014||RTOG||A Phase III Randomized Study of Patients With High Risk; Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade with Delayed Chemotherapy" Study Closed and Terminated||Adult CIRB - Late Phase Emphasis||Completed|
|S0012||SWOG||A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0023||SWOG||A Phase III Trial of Cisplatin/Etoposide/ Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0106||SWOG||A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Completed|
|S0124||SWOG||Randomized Phase III Trial of Cisplatin (NSC-119875) and Irinotecan (NCSC-616348) Versus Cisplatin and Etoposide (NSC-141540) in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)||Adult CIRB - Late Phase Emphasis||Completed|
|S0200||SWOG||A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy||Adult CIRB - Late Phase Emphasis||Completed|